Latest news and press releases about Kymera Therapeutics, Inc. (KYMR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins.
Price
| Price | $116.33 |
| Market Cap | $9.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 7.56 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 101.98% |
| Operating Margin | -333.54% |
| Net Margin | -285.41% |
Related companies: AAPG · ACAD · ACLX · AKRO · CRNX · IMVT · NAMS
Explore sector: Healthcare · Biotechnology
More sections of KYMR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks